Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma-Reply.

Sinnamon AJ, Gimotty PA, Karakousis GC.

JAMA Oncol. 2018 Aug 1;4(8):1136-1137. doi: 10.1001/jamaoncol.2018.0898. No abstract available.

PMID:
29902301
2.

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Uno H, Kim DH, Wei LJ.

JAMA Oncol. 2018 Aug 1;4(8):1135-1136. doi: 10.1001/jamaoncol.2018.0881. No abstract available.

PMID:
29902302
3.

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Sinnamon AJ, Neuwirth MG, Gimotty PA, Gangadhar TC, Amaravadi RK, Schuchter LM, Karakousis GC.

JAMA Oncol. 2018 Jan 1;4(1):126-128. doi: 10.1001/jamaoncol.2017.3462. No abstract available.

4.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

5.

Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.

McKean MA, Amaria RN.

Am J Clin Dermatol. 2018 Oct;19(5):639-646. doi: 10.1007/s40257-018-0371-8.

PMID:
30039289
6.

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.

Goldman C, Tchack J, Robinson EM, Han SW, Moran U, Polsky D, Berman RS, Shapiro RL, Ott PA, Osman I, Zhong H, Pavlick AC, Wilson MA.

Oncology. 2017;93(3):164-176. doi: 10.1159/000475715. Epub 2017 Jun 10.

PMID:
28601879
7.

Treatment of metastatic melanoma: a multidisciplinary approach.

Fava P, Astrua C, Sanlorenzo M, Ribero S, Brizio M, Filippi AR, Marra E, Picciotto F, Sangiolo D, Carnevale-Schianca F, Aglietta M, Sandrucci S, Ricardi U, Caliendo V, Quaglino P, Fierro MT.

G Ital Dermatol Venereol. 2017 Jun;152(3):241-261. doi: 10.23736/S0392-0488.17.05633-4. Epub 2017 Mar 14. Review.

PMID:
28290625
8.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.

Melanoma Res. 2017 Aug;27(4):358-368. doi: 10.1097/CMR.0000000000000359.

9.

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.

Lau PK, Ascierto PA, McArthur G.

Curr Opin Immunol. 2016 Apr;39:30-8. doi: 10.1016/j.coi.2015.12.006. Epub 2016 Jan 5. Review.

PMID:
26765776
10.

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.

Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS.

Melanoma Res. 2019 Jun;29(3):301-310. doi: 10.1097/CMR.0000000000000504.

11.

Major Changes in Systemic Therapy for Advanced Melanoma.

Thompson JA.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):638-40.

PMID:
27226502
12.

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C.

Eur J Cancer. 2017 Sep;83:247-257. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review.

PMID:
28756137
13.

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.

Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.

Eur J Cancer. 2018 Jul;98:10-16. doi: 10.1016/j.ejca.2018.04.010. Epub 2018 May 26.

PMID:
29843107
15.

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.

Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D.

J Immunother Cancer. 2017 Feb 21;5:8. doi: 10.1186/s40425-017-0210-0. eCollection 2017.

16.

Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.

Nakamura Y, Fujisawa Y, Tanaka R, Maruyama H, Ishitsuka Y, Okiyama N, Watanabe R, Fujimoto M.

J Dermatol. 2018 Nov;45(11):1337-1339. doi: 10.1111/1346-8138.14637. Epub 2018 Sep 11.

PMID:
30204266
17.

Successes and limitations of targeted cancer therapy in melanoma.

Romano E, Michielin O.

Prog Tumor Res. 2014;41:78-88. doi: 10.1159/000355903. Epub 2014 Feb 17. Review.

PMID:
24727988
18.

Immune checkpoint blockade.

Naidoo J, Page DB, Wolchok JD.

Hematol Oncol Clin North Am. 2014 Jun;28(3):585-600. doi: 10.1016/j.hoc.2014.02.002. Review.

PMID:
24880949
19.

Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.

Sullivan RJ, Flaherty KT.

Clin Cancer Res. 2015 Jul 1;21(13):2892-7. doi: 10.1158/1078-0432.CCR-14-3061. Epub 2015 Apr 30.

20.

The impact of effective systemic therapies on surgery for stage IV melanoma.

Smith MJF, Smith HG, Joshi K, Gore M, Strauss DC, Hayes AJ, Larkin J.

Eur J Cancer. 2018 Nov;103:24-31. doi: 10.1016/j.ejca.2018.08.008. Epub 2018 Sep 7.

PMID:
30196107

Supplemental Content

Support Center